Eucrisa Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Dec, 2029

(5 years from now)

US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(5 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(6 years from now)



Eucrisa is a drug owned by Anacor Pharmaceuticals Inc. It is used for managing mild to moderate atopic dermatitis. Eucrisa uses Crisaborole as an active ingredient. Eucrisa was launched by Anacor Pharms Inc in 2016. It is is available in ointment form for topical use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 20, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2021
New Patient Population(NPP) Mar 23, 2023
Pediatric Exclusivity(PED) Sep 23, 2023
New Dosing Schedule(D-191) Apr 03, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents